Lupin is introducing rivaroxaban tablets, 2.5 mg, which is the generic of Janssen’s Xarelto.

Mumbai: Global pharma major Lupin Limited has announced that it has launched Rivaroxaban Tablets USP, 2.5 mg, following the final approval of its Abbreviated New Drug Application (ANDA) from ...

Global pharma major Lupin Limited (Lupin) announced that it has launched rivaroxaban tablets USP, 2.5 mg, following the final approval of its Abbreviated New Drug Application from the US FDA.

Two companies have received approved for a generic of the 2.5 mg tablet of anticoagulant rivaroxaban, which is used to reduce ...

A big dampener to Lupin’s plans would be the potential imposition of tariff on pharma products by the Trump government.

Citi said the company's announcement of generic Rivaroxaban 2.5 mg (Xarelto 2.5mg) tablets in the US is an "at risk" launch as the patent litigation is still ongoing. The patent will expire in 2039.

Rivaroxaban 2.5 mg tablets from Lupin and Taro are now considered therapeutic equivalents to name-brand rivaroxaban (Xarelto). Low-dose rivaroxaban is indicated to reduce the risk of major ...

Lupin's shares increased by 21.51% over the past year. However, year-to-date (YTD), the stock has decreased by 14.21%. Over the last six months, the price fell by 10.12%, while in the past three ...

The approval is only for the 2.5mg tablet. Xarelto is also available in 10mg, 15mg, and 20mg tablets, as well as an oral suspension (1mg/mL), to treat various conditions.